D tier · weak
Graded D because glutathione's endogenous biochemistry is textbook-solid but the injectable route has almost no controlled human evidence - the flagship cosmetic use rests on a single trial that reviewers called dubious in design and flawed in analysis - and multiple national regulators have issued warnings against it.
glutathione
Glutathione is a well-characterised endogenous thiol tripeptide central to cellular redox defence and phase II detoxification, but the evidence for administering it by injection or infusion is exceptionally thin. A published review found only one intravenous clinical trial for the popular skin-lightening use, and the Philippine FDA and other regulators have warned that no injectable product is approved for that purpose.
// we supply this one
available as a research reagent
≥ 98% HPLC · lyophilised powder · batch certificate published. Grade D above is our own and is not adjusted because we stock it.
the explanation
Glutathione is a natural antioxidant your cells make and use constantly, and nobody disputes that it matters biologically. What is disputed is whether injecting it does anything useful, because the controlled human studies barely exist and health regulators have specifically warned against IV glutathione drips for skin whitening.
regulatory status
No approved injectable product for cosmetic use; multiple regulator warnings
Philippine FDA Advisory No. 2019-182 states that 'The FDA has not approved any injectable products for skin lightening' and warns of liver, kidney and nervous-system toxicity, Stevens-Johnson Syndrome, and transmission of infectious agents such as HIV and hepatitis B and C. The Philippine Department of Health has repeatedly warned against intravenous glutathione for skin whitening. A published dermatology review notes that parenteral glutathione is approved only for severe liver disorders and prevention of chemotherapy-associated neurotoxicity in the jurisdictions where it is registered at all, and that a lack of statutory regulation in most countries has enabled unchecked cosmetic use. Oral glutathione is separately marketed as a dietary supplement, a different regulatory category from injectable material.
how it works · proposed mechanism
Glutathione is the cell's principal thiol redox buffer and a conjugation substrate for detoxification, but its behaviour as an injected drug is a separate question from its endogenous role.
Redox buffering and cycling
The cysteine thiol reduces peroxides via glutathione peroxidase, cycling between reduced GSH and oxidised GSSG. The GSH/GSSG ratio is a standard readout of intracellular oxidative state.
Phase II conjugation
Glutathione S-transferases conjugate GSH to electrophilic xenobiotics, forming mercapturate precursors for renal excretion. This is the basis of its established role in paracetamol toxicity via its precursor N-acetylcysteine.
Proposed tyrosinase interference
The cosmetic rationale holds that glutathione shifts melanogenesis from eumelanin toward lighter pheomelanin and chelates tyrosinase copper. This mechanism is proposed rather than demonstrated in controlled human intravenous studies.
what’s reported
evidence shape
6 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
An enormous global market for glutathione infusions rests on a published evidence base of essentially one intravenous trial that reviewers described as having a dubious study design and apparently flawed analysis. The route with the least evidence is the route being sold hardest, and it is the route that carries the sterility, anaphylaxis and bloodborne-infection risks that oral use does not.
key published findings
- Human evidence audit: Sonthalia et al (Dermatology Practical & Conceptual, 2018;8(1)) identified only four clinical trials of glutathione for skin lightening across all routes - one intravenous, two oral or sublingual, and one topical.
- Human evidence quality: the same review concluded that 'The current clinical evidence of intravenous glutathione for skin lightening is limited to a single study with a dubious study design and apparently flawed analysis of results, casting doubt on the drug's efficacy and reported adverse effects.'
- Human trial: Hauser RA, Lyons KE, McClain T, Carter S and Perlmutter D published a randomized, double-blind pilot evaluation of intravenous glutathione in Parkinson's disease (Movement Disorders 2009;24:979-983). This index verified the citation but could not access a full text to verify the reported effect sizes, so no efficacy numbers are asserted here.
- Comparative route finding: the two oral and one topical trials in the Sonthalia review reported a good safety profile with appreciable but reversible effects on skin tone, meaning the better-evidenced routes are also the non-injectable ones.
- Regulatory finding: Philippine FDA Advisory No. 2019-182 states that no injectable products have been approved for skin lightening, and lists liver, kidney and nervous-system toxicity, Stevens-Johnson Syndrome, and transmission of HIV, hepatitis C and hepatitis B among the risks.
limitations of the evidence
- The intravenous evidence base is a single study of contested quality, so no reliable effect estimate for injected glutathione exists for the cosmetic indication at all.
- The Parkinson's disease study was explicitly a pilot evaluation, meaning it was sized to assess feasibility and tolerability rather than to detect a clinical effect.
- Systemic glutathione is degraded extracellularly by gamma-glutamyl transpeptidase and intracellular pools are replenished by de novo synthesis rather than intact uptake, so raising plasma concentration does not straightforwardly raise tissue concentration - a pharmacokinetic obstacle the cosmetic literature does not resolve.
documented safety signals
- Philippine FDA Advisory No. 2019-182 warns of liver, kidney and nervous-system toxicity associated with unapproved injectable skin-lightening use.
- Stevens-Johnson Syndrome is named explicitly in the same advisory as a reported severe cutaneous adverse reaction.
- Transmission of bloodborne infectious agents including HIV, hepatitis B and hepatitis C is listed as a documented risk, reflecting that these infusions are frequently administered in non-clinical cosmetic settings with inadequate sterile technique.
- The advisory also flags kidney stones and haemodialysis requirement associated with the intravenous vitamin C commonly co-infused in these drips, including in patients with G6PD deficiency - a co-administration hazard rather than a glutathione effect per se, but a real feature of how the product is used.
- Theoretical long-term risk raised in the regulatory literature: suppressing melanin production may reduce photoprotection, with unresolved concern about skin cancer risk over time.
- The Philippine Department of Health has issued repeated public warnings against intravenous glutathione for skin whitening, indicating a persistent pattern of harm rather than isolated incidents.
- There is no approved injectable product for cosmetic use in the United States or the Philippines, so material in circulation is compounded or unregulated, with unverified sterility, endotoxin content and concentration.
- Injectable administration by definition carries anaphylaxis, injection-site infection, abscess and thrombophlebitis risks that oral supplementation does not, and these are borne for an indication with no established efficacy.
identity
| full name | Glutathione (Injectable / Intravenous) |
| category | Longevity |
| modality | small molecule |
| formula | C10H17N3O6S |
| molar mass | 307.33 g/mol |
| cas | 70-18-8 |
| sequence | gamma-L-Glu-L-Cys-Gly (tripeptide with a non-standard gamma-glutamyl linkage; synthesised enzymatically, not ribosomally) |
laboratory handling
| storage | Reduced glutathione is oxidation-sensitive; lyophilised material is typically stored refrigerated at 2-8 C, protected from light and moisture, and solutions oxidise to GSSG on standing. No FDA-approved injectable product exists in the US to specify approved storage conditions. |
| solubility | Freely soluble in water; solutions are acidic and prone to air oxidation to the disulfide GSSG, so they are not stable on prolonged storage. |
| co-studied with | Commercial glutathione infusions are commonly sold combined with high-dose intravenous vitamin C, and the Philippine FDA advisory attributes specific harms - kidney stones in acidic urine, and haemodialysis requirement in G6PD-deficient patients - to that vitamin C component rather than to glutathione. This index does not describe regimens; it notes only that the combination adds documented risks to an indication with no established benefit. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedPhilippine Food and Drug Administration · 2019 · official
PubChem, U.S. National Library of Medicine · 2025 · official
Dermatology Practical & Conceptual 8(1) · 2018 · review
International Journal of Dermatology · 2025 · review
Philippine Daily Inquirer · 2024 · review
Movement Disorders 24:979-983 · 2009 · randomized
others in Longevity